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Background: Recent advances in lung cancer biology presuppose its inflammatory origin. In this regard, LTB-4 and
IL-8 are recognized to play a crucial role in neutrophil recruitment into airways during lung cancer.
Notwithstanding the intriguing hypothesis, the exact role of neutrophilic inflammation in tumour biology remains
complex and not completely known.
The aim of this study was to give our contribution in this field by investigating LTB-4 and IL-8 in the breath
condensate of NSCLC patients and verifying their role in cancer development and progression.
Method: We enrolled 50 NSCLC patients and 35 controls. LTB-4 and IL-8 concentrations were measured in the
breath condensate and the blood of all the subjects under study using EIA kits. Thirty NSCLC patients and ten
controls underwent induced sputum collection and analysis.
Results: LTB-4 and IL-8 resulted higher in breath condensate and the blood of NSCLC patients compared to
controls. Significantly higher concentrations were found as the cancer stages progressed. A positive correlation was
observed between exhaled IL-8 and LTB-4 and the percentage of neutrophils in the induced sputum.
Conclusion: The high concentrations of exhaled LTB-4 and IL-8 showed the presence of a neutrophilic
inflammation in the airways of NSCLC patients and gave a further support to the inflammatory signalling in lung
cancer. These exhaled proteins could represent a suitable non-invasive marker in the diagnosis and monitoring of
lung cancer.
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Background
Recent advances in cancer biology point to a role of
inflammatory signalling in lung cancer and encourage
the reconsideration of the diagnostic and prognostic
value of inflammatory markers.
Currently there is a large number of clinical data con-
firming the inflammatory origin of lung cancer: 1) in the
lung, chronic inflammatory diseases such as sarcoidosis,
fibrosis or chronic obstructive pulmonary disease
(COPD) have been associated with a higher risk of can-
cer development [1-7]; 2) several studies demonstrated
that human lung-cancer risk can be modified by poly-
morphisms in pro-inflammatory genes such as
interleukin (IL)-1 beta and the tumor necrosis factor
(TNF)a [8,9]; 3) other studies showed that long-term
users of anti-inflammatory drugs may be at a reduced
risk of cancer development [10].
The inflammatory processes in the lung are character-
ized by the influx of neutrophils into the airways
[11,12]. The migration and activation of leucocytes
within the airways may be the consequence of soluble
proteins released by resident cells that are activated by
various stimuli. Leukotriene (LTB)-4 and IL-8 are recog-
nized to play a crucial role in neutrophil recruitment
into airways during lung cancer [13,14].
LTB-4 is a lipoxygenase product of arachidonic acid
metabolism, released primarily by polymorphonuclear
and mononuclear phagocytes as well as by epithelial
cells [15-18]. LTB-4 is usually used as an indicator of
the state of activation of neutrophils [19]. LTB-4
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[19] but have not as yet been measured in other airway
samples of lung cancer patients.
Interleukin-8 (IL-8), one of the ELR+ CXC families of
chemokines, is a potent pro-angiogenic factor and
furthermore, its expression is associated with angiogen-
esis, tumour progression and survival in patients with
non-small cell lung cancer (NSCLC) [20-27]. Several
studies in blood and airways (broncho-alveolar lavage,
pleural effusion, tumour tissue) supported its role as
marker of lung cancer [19,22,28-31]. Recently higher
levels of IL-8 have been described, also in the exhaled
breath condensate (EBC) of NSCLC patients [32].
An increasing interest has been recently generated
among non-invasive methods that sample airways by the
collection of EBC, often more used for the biological
study of lung diseases, such as cancer [33]. The com-
plete non-invasiveness of this method makes the latter
more readily accepted by patients, such as those affected
by cancer, who are likely to already be exhausted, not
only by their condition, but also by the huge number of
exams they have had to undergo. Although the study of
tumour markers in exhaled breath condensate did not
reach the clinical settings, except in asthma and COPD,
a good number of studies are readily available in litera-
ture and propose the use of this sample for the non-
invasive diagnosis and monitoring of lung cancer
[28,32,34-36].
The aim of the present study was to give further sup-
port to the neutrophilic inflammatory signalling in lung
cancer analysing the LTB-4 and the IL-8 in the EBC of
NSCLC patients and controls.
Methods
Characteristics of the Patients
50 consecutive patients affected by non-small cell lung
cancer and 35 control subjects (without pulmonary dis-
eases) who consented to the study, were enrolled at the
U n i to fT h o r a c i cS u r g e r y ,C a s ad ic u r aL aM a d o n n i n a ,
Bari, and at the Department of Respiratory Disease, Fog-
g i aU n i v e r s i t y( T a b l e1 ) .W r i t t e ni n f o r m e dc o n s e n tw a s
obtained from all subjects upon approval of the study by
the Ethic Committees of the two hospitals.
All the patients were enrolled in the study immedi-
ately before histological diagnosis. Furthermore, none of
them had received any form of anti-cancer therapy,
invasive diagnostic procedure or primary lung surgery.
Following cytohistological diagnosis, patients with can-
cer underwent standard staging procedures consisting of
a physical examination, serum chemistry analysis, brain,
chest and abdomen CT scans, radionuclide bone scan,
and bronchoscopy. The diagnosis of NSCLC was done
either by bronchoscopic biopsy or by transthoracic nee-
dle aspiration. Squamous cell carcinoma was diagnosed
in twenty-two subjects, whereas the remaining subjects
received a cytohistological diagnosis of adenocarcinoma.
Overall, NSCLC patients were classified as stage I in 13
cases, stage II in 12 cases, stage III in 8 cases and stage
IV in 17 cases.
All of the patients enrolled underwent exhaled breath
condensate (EBC) and whole-blood (WB) collection at
enrolment. The day after the subjects underwent
induced sputum collection and analysis.
We acquired information on their smoking habits and
classified the smokers (according to the number of
pack-years smoked) into two groups: mild (group 1
[patients]: <40 pack-years) and heavy smokers (group 2
[patients]: >40 pack-years). Twenty-five of the lung can-
cer patients were current smokers (54 ± 8 pack/year);
fifteen were ex-smokers (44 ± 6 pack/year) and had quit
at least three years before, whereas ten were non-smo-
kers. Ten healthy subjects were smokers while the
remaining ones were non-smokers.
EBC and WB collection and processing
1 mL of EBC and 3 mL of WB in one setting from each
patient.
The EBC was collected by using a condenser, which
allowed for the non-invasive collection of non-gaseous
components of the expiratory air (EcoScreen Jaeger,
Wurzburg, Germany). The condensate was collected in
ice at -20°C, transferred to 1,5 ml polypropylene tubes,
and immediately stored at -70°C for subsequent analysis.
In addition, whole blood was processed within 2 hrs of
sample collection, transferred into polypropylene tubes,
and stored at -20°C until further use.
Table 1 Demographic and clinical data of subjects
enrolled
NSCLC patients healthy subjects
N5 0 3 5
sex (M/F) 36/14 18/17
AGE (yr) 65 ± 7 64 ± 1
FEV1 98.7 ± 3.4 101 ± 3.3
FVC 100 ± 3.2 102.1 ± 2.7
Hystotype:








current smokers 25 10
ex-smokers 15 -
non-smokers 10 25
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According to the method described by Spanevello et al.,
the sputum was induced through inhalation of hyper-
tonic saline solution (4.5%) with an ultrasonic nebulizer
(DeVilbiss 65; DeVilbiss Corporation, Somerset, PA) and
analysed after plug selection [37].
Measurement of LTB-4 and IL-8
A specific enzyme immunoassay (Cayman Chemical,
Ann Arbor, MI and Thermoscientific, Rockford, IL,
USA) was used to measure LTB-4 and IL-8 in breath
condensate and whole blood. The intra-assay and inter-
assay variability were less than 10%. The specificity was
100%, and the detection limits of the assay were 3 pg/ml
and 2 pg/ml. We tested the reproducibility of the
repeated measurements of LTB-4 and IL-8 by means of
the Bland and Altman test and with the variation coeffi-
cient [38].
Statistical analysis
The data were not normally distributed and therefore
non-parametric tests were chosen for analysis. The data
were expressed as a median (25% percentile-75% per-
centile). A Mann-Whitney test was used to compare the
groups, and the correlations between variables were per-
formed using the Spearman’s rank correlation test. Sig-
nificance was defined as a p value of < 0.05.
Statistical analysis was carried out using a SATA 10
MP for MAC OS × software package. The data were
analyzed by the Department of Medical Sciences, Sec-
tion of Hygiene, University of Foggia and Apulia Regio-
nal Epidemiological Observatory, Italy.
Results
LTB-4 measurement
LTB-4 levels were significantly higher in the EBC of
N S C L Cp a t i e n t st h a ni nt h eE B Co fc o n t r o ls u b j e c t s
[43.5 (35.1-56.5) vs 15.9 (7.9-23.5) pg/ml, p < 0.001]
(Figure 1, panel A). Significantly higher concentrations
of LTB-4 were observed in the whole blood of NSCLC
patients than in controls [44.1 (21.7-69.5) vs 17.9 (13.4-
31.2) pg/ml, p < 0.001]. Progressively higher concentra-
tions of LTB-4 in EBC were found from stage I to stage
IV [29.8 (24.2-31.2), 40.3 (39.0-42.2), 51.2 (45.2-55.2)
and 57.9 (53.8-61.5) pg/ml] (Figure 2, panel A). Signifi-
cant differences between each stage and the next one
were observed (p < 0.005).
No difference in exhaled LTB-4 levels was reported
among the histological types of NSCLC.
Higher levels of exhaled LTB-4 were found in smokers
than in non-smokers both in the case of NSCLC
patients and controls [47.9(18.9-62.8) vs 33.4 (17.9-48.3)
pg/ml, p < 0.001 and 18.4 (13.5-23.5) vs 12.3 (7.9-16.8)
pg/ml, p < 0.005)] (Figure 3, panel A). Increased levels
of exhaled LTB-4 were observed in group 2 with respect
to group 1 in NSCLC patients [60.6 (44.3-62.8) vs 35.3
(18.9-44.3) pg/ml, p < 0.001]. A positive correlation was
found between LTB-4 concentrations in EBC and neu-
trophils in the induced sputum (r = 0.7, p < 0.001).
No correlation was observed between LTB-4 concen-
trations in EBC and other clinical and demographic
data.
IL-8 measurement
IL-8 levels were significantly higher in EBC of NSCLC
patients than in EBC of control subjects [28.1 (10.3-44.2)
vs 10.7 (4.1-23.4) pg/ml, p < 0.001] (Figure 1, panel B).
Significantly higher concentrations of IL-8 were observed
in whole blood of NSCLC patients than in controls [38.7
(27.1-50.2) vs 16.4 (10.2-22.6) pg/ml, p < 0.001]. Progres-
sively higher concentrations of IL-8 in EBC were found
from stage I to stage IV [15.5 (10.3-20.1), 21.9 (12.3-
30.1), 31.3 (26.1-37.1) and 40.5 (36.1-44.2) pg/ml] (Figure
2, panel B). Significant differences between each stage
and the next one were observed (p < 0.005).
No difference in exhaled IL-8 levels was reported
between the histological types of NSCLC.
Higher levels of exhaled IL-8 were found in smokers
than in non-smokers both in NSCLC patients and in
controls [38.3(30.6-44.2) vs 19.4 (10.3-30.1) pg/ml, p <
0.001 and 13.2 (13.5-23.4) vs 7.3 (4.1-13.4) pg/ml, p <
0.005] (Figure 3, panel B). Increased levels of exhaled
IL-8 were observed in group 2 with respect to group 1
in NSCLC patients [40.3 (37.8-44.2) vs 32.3 (27.1-40.2)
pg/ml, p < 0.001]. A positive correlation was observed
between IL-8 concentrations in EBC and neutrophils in
the induced sputum (r = 0.7, p < 0.001).
No correlation was observed between IL-8 concentra-
tions in EBC and other clinical or demographic data.
Cytology in the induced sputum
Twenty NSCLC patients and twenty-five healthy sub-
jects were not able to produce adequate sputum samples
(defined as containing at least 500 non-squamous cells)
and their expectorates were discharged.
The percentage of neutrophils was higher in the
NSCLC patients than in the controls [32.3 (27.5-36.2) vs
10.4 (8.3-13.7); p < 0.01]. The percentage of macro-
phages was lower in the NSCLC patients than in the
controls [63.4 (55.1-71.6) vs 85.8 (78.4-87.9); p < 0.01],
whereas no significant differences were observed in the
percentage of eosinophils [1.2 (0.9-2.0) vs 1.2 0.8-2.0)],
lymphocytes [1.0 (0.3-2.0) vs 1.0 (0.8-1.9)] and epithelial
cells [OO: 0.9 (0.6-1.7) vs 0.9 (0.6-1.9)].
Discussion
The concentrations of LTB-4 and IL-8 explored by the
present study were found to be higher in the exhaled
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compared to controls, particularly in smokers and ex-
smokers rather than in non-smokers. An overproduction
of LTB-4 and IL-8 in the EBC of subjects with more
advanced stages of lung cancer and a relation to cancer
progression were further described. Finally, we reported
a positive correlation between exhaled LTB-4 and IL-8
and the percentage of neutrophils in the sputum.
One recent intriguing theory on lung cancer patho-
genesis supposed that chronic inflammation can
Figure 1 LTB-4 (Panel A) and IL-8 (Panel B) levels were significantly higher in the EBC of NSCLC patients than in the EBC of control
subjects (p < 0.001).
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genesis. Neutrophils seem to be the main orchestrators,
fighting against cancers by eradicating dysplastic and
neoplastic cells. Moreover, these inflammatory cells can
be manipulated to induce an immune escape of cancer
cells, especially in a tumour-promoting micro-environ-
ment, which is created by a chronic inflammation seen
i nl u n g s[ 2 0 ] .F u r t h e r m o r e ,r e p e a t e dl u n gi n j u r ya n d
repair triggered by chronic inflammation enhance cell
turnover and potential genetic error, as well as epithe-
lial-to-mesenchymal transition and ultimately lead to
lung tumorigenesis [39]. Regrettably, notwithstanding
the recent increasing interest in the neutrophilic inflam-
matory origin of lung cancer, the role of inflammation
and immunity in tumour biology remains complex and
not completely known.
In order to give a contribution to this curious inflam-
matory origin of lung tumour, we studied two known
Figure 2 Progressively higher concentrations of LTB-4 (Panel A) and IL-8 (Panel B) in EBC were found from stage I to stage IV.
Significant differences between each stage and the next one were observed (p < 0.005).
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IL-8, in the airways and blood of patients affected by
lung cancer.
Several previous studies analysed these proteins in
lung cancer patients and described high levels of LTB-4
and IL-8 in tumour tissue [31], pleural effusion [19,22],
BAL [30] and serum [28-30].
In accordance with previous results, we confirmed the
increase of LTB-4 and IL-8 in the systemic compartment
and in the airways, reporting higher concentrations in
the whole-blood and breath condensate of NSCLC
patients compared to controls.
Both the LTB-4 and the IL-8 have been previously
measured as neutrophilic markers in the breath conden-
sate of patients affected by lung inflammatory diseases
[40-43]. In the light of the trendiness of studies of
tumour markers in the exhaled breath condensate, for
the complete non-invasiveness of this collection method,
Figure 3 LTB-4 (Panel A) and IL-8 (Panel B) levels were significantly higher in the EBC of smokers compared to non smokers either in
NSCLC or in healthy group (p < 0.001, p < 0.005).
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ethic committees, IL-8 was also recently measured in
the breath condensate of NSCLC patients. In this
regard, however, contrasting data are available: in one
study the exhaled IL-8 did not result as indicative of
lung cancer [32], while in another its levels decreased
after two cycles of chemotherapy [28]. In accordance
with the Jungraithmayr study, we observed that exhaled
IL-8 reflects cancer biology as its concentrations
increased in lung cancer patients compared to controls,
particularly when progressing to the next stage of can-
cer. We reported the same behaviour also for LTB-4,
which we measured in this case for the first time in the
breath condensate of lung cancer patients.
Our findings on the role of LTB-4 and IL-8 in the
progression of lung tumours were not surprising in con-
sideration of the fact that previous studies indicated that
these proteins possess angiogenic and direct mitogenic
effects. Higher concentrations of both markers were in
fact largely described in loco regional relapse as well as
the metastasis of lung cancer [20,23-26,44].
Notwithstanding the numerous studies, none reported
differences in the LTB-4 and IL-8 levels in adenocarci-
noma and squamous cell carcinoma. Moreover, in this
study we did not observe any correlation with any hys-
topathological type as similar concentrations of exhaled
LTB-4 and IL-8 were found in both hystotypes.
Another interesting result of this study was the higher
concentration of IL-8 and LTB-4 that we described in
smokers rather than in non-smokers. This is perfectly in
line with what was suggested by Pickett [45], who
showed changes in cytokine production in primary-nor-
mal human bronchial epithelial cells following treatment
for 18 hrs with cigarette smoke condensates. The
increase of these proteins in smokers suggests that the
increased inflammatory cells in airways, largely
described in smokers, are another possible source of
these proteins. In detail, the polymorphonuclear cells
seem to be involved in the production and release of
LTB-4 and IL-8 [15-18] as was also proved by the posi-
tive correlation that we reported between these exhaled
proteins and the percentage of neutrophils in the spu-
tum. However, as previously suggested by Petrin and
Fudala, this correlation may also be the result of the
chemoactractant or pro-survival properties of these
mediators [46,47]. In this regard, the study of Pace et al
demonstrated [19] that LTB4 is an indicator of the state
of activation of neutrophils [19] as well as stimulating
peripheral blood neutrophils to synthesize and secrete
biologically active IL-8 [48].
Although healthy smokers showed higher levels of
e x h a l e dI L 8a n dL T B 4c o m p a r e dt on o n - s m o k e r s ,t h e
concentrations of both markers were significantly higher
in NSCLC patients (smokers and non-smokers),
allowing us to suggest that their increase is not only due
to cigarette smoke but is also the effect of lung cancer.
In this study we support and encourage the use of the
breath condensate in lung cancer studies in the light of
the non-invasiveness of this method that, especially in
lung cancer patients, where possible, is auspicable in
view of the emotional and practical stress that patients
underwent.
Conclusion
In this study we support the key role of neutrophilic air-
ways inflammation in lung carcinogenesis and highlight
the potentiality of LTB-4 and IL-8 as markers of lung
cancer development and progression [30,31,39].
This said, although further studies are needed to con-
firm our data, we believe that the measurement of LTB-
4 and IL-8 in breath condensate could soon be proposed
in the diagnosis and monitoring of NSCLC. This can be
justified when one bears in mind the non-invasiveness
of this method, not to mention the fact that it lends
itself particularly well to the early screening and follow-
up of lung cancer.
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